



## *Clostridioides difficile* Infection, 2nd Edition

Guest Editor:

**Dr. Guido Granata**

Clinical and Research

Department, National Institute  
for Infectious Diseases “L.

Spallanzani” IRCCS, Rome, Italy

Deadline for manuscript  
submissions:

**closed (31 March 2024)**

### Message from the Guest Editor

Dear Colleagues,

The first volume of the Special Issue “*Clostridioides difficile* Infection” was published in 2021. It was a successful issue, with 9 published papers. These papers shed light on several aspects of this complex disease, including the *Clostridioides difficile* infection (CDI) clinical course and the mortality rate in different settings and patients’ case mix, the novel risk factors for CDI recurrence and novel therapeutic approaches. This result encouraged us to open a second volume on the same topic.

As a continuation of the Special Issue published in 2021, this second volume will also deliver an invaluable compendium of the latest studies on any aspects concerning CDI.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Nicholas Dixon

School of Chemistry and  
Molecular Bioscience, University  
of Wollongong, Wollongong, NSW  
2522, Australia

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1  
(*General Pharmacology, Toxicology and Pharmaceutics*)

## Contact Us

*Antibiotics* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/antibiotics](http://mdpi.com/journal/antibiotics)  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)  
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)